Best of BS Opinion: Covaxin gets a booster, pandemic risk in IPOs, and more

Here are the best of BS Opinion pieces of the day

After a long delay, the World Health Organization has approved the Indian-manufactured vaccine Covaxin for emergency use. Scaling this hurdle – finally -- raises key questions about the next steps in the Covid-19 vaccination programme. The top edit outlines the key issues here. 

In other views:

The prime minister’s Panchamrita pledge at Glasgow burnishes India’s climate credentials, but a perilous future awaits the world. Shyam Saran discusses what’s at stake.  Read it here

The second edit explains how the renaming of Facebook will help the social media giant in multiple ways. Read it here

Covid-19 is a standard fixture in all IPO prospectuses hitting the market. Who will be the first to say the pandemic is a thing of the past, asks Nivedita Mookerji. Read it here

QUOTE OF THE DAY

 

‘They didn’t show up… It is a gigantic issue and they just walked away’

 

US President Joe Biden on Xi Jinping’s absence at COP26